Eli Lilly and Co (LLY)

LLY (NYSE:Drugs)
$66.08
neg -0.45
-0.68%
Today's Range: 65.75 - 66.37 | LLY Avg Daily Volume: 3,696,500
Last Update: 09/22/14 - 4:00 PM EDT
Volume: 3,571,528
YTD Performance: 30.45%
Open: $66.19
Previous Close: $66.53
52 Week Range: $47.53 - $67.14
Oustanding Shares: 1,117,308,330
Market Cap: 74,401,561,695
6-Month Chart
TheStreet Ratings Grade for LLY
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 6 5 5 5
Moderate Buy 0 0 0 0
Hold 8 8 8 7
Moderate Sell 0 0 0 0
Strong Sell 1 1 1 2
Mean Rec. 2.29 2.38 2.38 2.52
Latest Dividend: 0.49
Latest Dividend Yield: 2.94%
Dividend Ex-Date: 08/13/14
Price Earnings Ratio: 21.14
Price Earnings Comparisons:
LLY Sector Avg. S&P 500
21.14 21.40 28.91
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
11.16% 23.52% 77.32%
GROWTH 12 Mo 3 Yr CAGR
Revenue 2.30 0.00 0.00
Net Income 14.60 -0.08 -0.03
EPS 18.00 -0.05 -0.02
Earnings for LLY:
EBITDA 6.99B
Revenue 23.11B
Average Earnings Estimates
Qtr (09/14) Qtr (12/14) FY (12/14) FY (12/15)
Average Estimate $0.68 $0.71 $2.79 $3.16
Number of Analysts 8 7 12 11
High Estimate $0.74 $0.74 $2.80 $3.39
Low Estimate $0.64 $0.67 $2.74 $2.97
Prior Year $1.11 $0.74 $4.15 $2.79
Growth Rate (Year over Year) -38.63% -3.86% -32.87% 13.40%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
Bullish
Aug 27, 2014 | 7:17 AM EDT
Coverage of LLY was started with a Buy rating, Deutsche Bank said. $71 price target. Company is poised to return to growth in the comin...
Bearish
Jul 31, 2014 | 8:08 AM EDT
LLY was downgraded to Neutral, Citigroup said. Alimta risks are under-appreciated in the market. 
If you insist on playing it, recognize the 50/50 nature of the scenario.

Off the Charts Real Money Pro($)

Marathon Oil and Morgan Stanley have traded through our entry prices.

Off the Charts Real Money Pro($)

Molson Coors doesn't offer a good entry point, but CME Group opens the door for shorts.
A wave of M&A in the health sector makes sense.

Eli Lilly Is Surging Real Money Pro($)

The shares are in full breakout mode today.
Update
May 06, 2014 | 6:50 AM EDT
LLY - Eli Lilly Annual Shareholder Meeting 
Bearish
Apr 23, 2014 | 7:51 AM EDT
LLY was downgraded from Buy to Neutral, Leerink Swann said. $61 price target. Company lacks near-term catalysts and made an expensive a...
Bullish
Apr 23, 2014 | 7:28 AM EDT
LLY raised its numbers, Jefferies said. Driven by accretive NAH acquisition. $60 price target and Hold rating. 

Columnist Conversations

After markets meet extensions of prior swings on the upside they are vulnerable to a deeper downside correctio...
Markets stage nice sell-off to begin trading week as S&P 500 2,000 continues to proves to be tough level t...
It's like somebody yelled fire in all three at the same time.
S&P futures and the FINAL hour: Short term oversold came earlier as the S&P ...

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.